E-Therapeutics plc (ETX)

Profile

https://www.maureletprom.fr

E-Therapeutics plc is a biotechnology company specializing in the integration of computational biology and RNA interference (RNAi) technologies to advance drug discovery. Its core focus lies in developing innovative RNAi medicines, leveraging proprietary platforms such as HepNet™, a hepatocyte-centric computational biology system, and GalOmic™, an advanced chemistry platform for generating potent and selective small interfering RNA (siRNA) therapeutics. These platforms enable the rapid identification and validation of novel gene targets, particularly within the liver, addressing complex diseases with high unmet medical needs. The company’s approach combines artificial intelligence, network biology, and in silico drug design to streamline research and development, making the process more efficient and data-driven. E-Therapeutics plc has demonstrated proof-of-concept with preclinical assets in therapeutic areas like metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration, haemophilia, and heart failure. By partnering with industry leaders and progressing a differentiated pipeline, the company plays a significant role in bridging biotechnology and computational science to accelerate the creation of next-generation RNAi therapies.